General Information of Drug Combination (ID: DC4P2O4)

Drug Combination Name
Liraglutide Insulin-aspart
Indication
Disease Entry Status REF
Diabetes Mellitus, Type II Phase 1 [1]
Component Drugs Liraglutide   DM3FXPS Insulin-aspart   DMX7V28
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Liraglutide
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Approved [2]
Type-2 diabetes 5A11 Approved [3]
Obesity 5B81 Phase 2 [3]
Liraglutide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Agonist [5]
------------------------------------------------------------------------------------
Liraglutide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Dipeptidyl peptidase IV (DPP4) DEKZQY6 DPP4_HUMAN Metabolism [6]
Neprilysin (MME) DEVN830 NEP_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Liraglutide Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Expression [7]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [7]
Disintegrin and metalloproteinase domain-containing protein 33 (ADAM33) OTRZVI77 ADA33_HUMAN Increases Expression [7]
------------------------------------------------------------------------------------
Indication(s) of Insulin-aspart
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [4]
Insulin-aspart Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Insulin (INS) TTZOPHG INS_HUMAN Modulator [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01654120) Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics
2 Liraglutide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1133).
4 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
5 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
6 Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010 Nov;38(11):1944-53.
7 Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.